Cargando…

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nogales, Vanesa, Reinhold, William C., Varma, Sudhir, Martinez-Cardus, Anna, Moutinho, Catia, Moran, Sebastian, Heyn, Holger, Sebio, Ana, Barnadas, Agusti, Pommier, Yves, Esteller, Manel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823092/ https://www.ncbi.nlm.nih.gov/pubmed/26625211 http://dx.doi.org/10.18632/oncotarget.6413

Ejemplares similares

CpG island hypermethylation-associated silencing of small nucleolar RNAs in human cancer
por: Ferreira, Humberto J., et al.
Publicado: (2012)

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

Aberrant DNA methylation profiles in the premature aging disorders Hutchinson-Gilford Progeria and Werner syndrome
por: Heyn, Holger, et al.
Publicado: (2013)

DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia
por: Ferreira, H J, et al.
Publicado: (2016)

Erratum: DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia
por: Ferreira, H J, et al.
Publicado: (2017)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

Mechanistic understanding of human SLFN11
por: Metzner, Felix J., et al.
Publicado: (2022)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
por: Ballestrero, Alberto, et al.
Publicado: (2017)

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
por: Moribe, Fumiya, et al.
Publicado: (2021)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
por: Moutinho, Catia, et al.
Publicado: (2013)

Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023)

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer
por: Xu, Qiao Ping, et al.
Publicado: (2023)

Characterization of Novel Ribosome-Associated Endoribonuclease SLFN14 from Rabbit Reticulocytes
por: Pisareva, Vera P., et al.
Publicado: (2015)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL
por: Goldshtein, Aviya, et al.
Publicado: (2016)

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES
por: Nakata, Satoshi, et al.
Publicado: (2022)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray
por: Moran, Sebastián, et al.
Publicado: (2014)

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
por: Páez, David, et al.
Publicado: (2018)

The putative RNase P motif in the DEAD box helicase Hera is dispensable for efficient interaction with RNA and helicase activity
por: Linden, Martin H., et al.
Publicado: (2008)

High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner
por: Varma, Sudhir, et al.
Publicado: (2014)

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia
por: Anadón, C, et al.
Publicado: (2017)

Role of the novel endoribonuclease SLFN14 and its disease-causing mutations in ribosomal degradation
por: Fletcher, Sarah J., et al.
Publicado: (2018)

Novel SLFN14 mutation associated with macrothrombocytopenia in a patient with severe haemorrhagic syndrome
por: Polokhov, Dmitrii, et al.
Publicado: (2023)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
por: Jo, Ukhyun, et al.
Publicado: (2021)

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
por: Mezzadra, Riccardo, et al.
Publicado: (2019)

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
por: Coleman, Niamh, et al.
Publicado: (2020)

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
por: Winkler, Claudia, et al.
Publicado: (2020)

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression
por: Fischietti, Mariafausta, et al.
Publicado: (2022)

Candidate biomarker assessment for pharmacological response
por: Reinhold, William C., et al.
Publicado: (2020)

A Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence
por: Berger, Michael, et al.
Publicado: (2010)

Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin
por: Peng, Yaojun, et al.
Publicado: (2019)

Study of Clinical Predictive Value and Immune Characterization of SLFN11 in Clear Cell Renal Cell Carcinoma
por: Liu, Yifu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4mcu4tkirofn6sfu53tg9s880m